Abstract: The present invention relates to effervescent compositions containing active ingredients, in particular dry plant extracts, wherein the acid donor of the effervescent couple is constituted by a dried fruit juice with a natural acid pH, such as freeze-dried citrus fruit juice.
Abstract: The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.
Abstract: The present invention includes a method for treating periodontal disease. The method comprises delivering to a pocket of a tooth with periodontal disease, a viscous, reddish-brown solution comprising sulfuric acid and sulphonated phenolic compounds. The method also comprises retaining the reddish-brown solution in the pocket for t time ranging from about 5 seconds to about 60 seconds.
Abstract: A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.
Type:
Grant
Filed:
June 16, 2003
Date of Patent:
December 7, 2004
Assignee:
AstraZeneca AB
Inventors:
Jan-Erik Löfroth, Staffan Schantz, Anders Welin, Lars Johan Pontus de Verdier Hjartstam
Abstract: A nutritional supplement for providing, and for promoting the health of salivary glands and/or supporting normal or healthy swallowing includes ingredients obtainable from turmeric, ginger, and horseradish. The nutritional supplement may also be used to treat symptoms such as symptoms of a common cold, sore throat, congestion, mucositis, laryngitis, mucous membrane inflammation and sialorrhea, as well as inflammation and viral infectin, or to inhibit or exterminate a virus. This nutritional supplement can be orally administered a person. The nutritional supplement may further include optional ingredients such as ingredients obtainable from slippery elm bark powder and green tea, as well as other optional ingredients. This nutritional supplement may further include a pharmaceutically acceptable carrier for oral administration.
Abstract: The invention relates to a process for preparing a soft tablet capable of being chewed or disintegrated in the oral cavity. The tablet is prepared by forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient energy, preferably in the form of heat, to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%.
Abstract: A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments.
Type:
Grant
Filed:
October 29, 2002
Date of Patent:
October 26, 2004
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Michael Cappola, George W. Gereg, Susan Way
Abstract: The present invention provides a method of treating farrowing sows to increase pig production including the steps of determining the zinc concentration of swine blood or tissue samples, comparing the determined concentration with a predetermined adequate concentration range for swine, and then supplying chelated zinc to the sows when the determined concentration is below the adequate concentration range. The chelated zinc may be supplied to the sows through the water or feed, or even supplied by injection. The chelated zinc is preferably supplied during the lactation period since this is the time when the zinc is most critical in determining increased production in future litters and conception rates. Zinc in the chelated form is readily available to the sow and therefore rapidly corrects any deficiency that may exist. An alternate embodiment of this invention includes supplying chelated manganese in addition to the chelated zinc.
Abstract: Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.
Abstract: A pharmaceutical delivery system comprising a slow-release formulation of vitamin C (ascorbic acid) and a plain-release formulation of vitamin E (tocopherol) has been found to raise and maintain the concentrations of these vitamins in the blood plasma to a ratio of approximately 2.2:1. The steady-state concentration and ratio of these antioxidants has been found to be critical in the prevention and treatment of oxidative stress related disorders such as arteriosclerosis and diabetes and neural degenerative disorders such as Alzheimer's Disease.
Type:
Grant
Filed:
August 21, 2000
Date of Patent:
October 19, 2004
Assignee:
Ferrosan A/S
Inventors:
Bent Højgaard, Henrik Enghusen Poulsen, Jukka Salonen
Abstract: A shaving composition containing a skin-tightening effective amount of an astringent additive, wherein the shaving composition is applied onto human skin prior to shaving.
Abstract: A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
Type:
Grant
Filed:
November 3, 2000
Date of Patent:
September 14, 2004
Assignee:
Andrx Labs, LLC
Inventors:
Xiu Xiu Cheng, Chih-Ming Chen, Steve Jan, Joseph Chou
Abstract: There is disclosed a method for stopping bleeding and forming black blood coagulation on contact, comprising administering powdered L-threo-hex-2-enono-1,4-lactone thereof to a bleeding site in an amount of 0.1568 grams for every milliliter of blood. This includes cancer, liver diseases and hemophiliac bleeding in patients or animals in whom the thrombocytopenia or coagulation factors disorders result. Accordingly, the said mechanism of action of powdered L-threo-hex-2-enono-1,4-lactone in the formation of blood coagulation on contact is the unique common pathway for all blood coagulations, which overturns the mechanisms of intrinsic and extrinsic pathways for blood coagulation cascade being the unique pathways for blood coagulation in which the coagulation factors 1, 2, 5, 7, 8, 9, 10 and platelet factor 3 are essential for the pathways.
Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.
Type:
Grant
Filed:
July 16, 2001
Date of Patent:
August 10, 2004
Assignee:
Bayer AG
Inventors:
Gerhard Franckowiak, Hubert Appolt, Gregor Leifker, Hans-Peter Wirges, Wolfram Ledwoch
Abstract: The invention relates to porous, rapidly disintegrating, active substance-containing pellets based on chitosan or a basic chitosan derivative, manufactured according to a dripping method wherein an aqueous solution or dispersion of chitosan or a basic chitosan derivative, one or more active substances, possibly further active substances and an acid is dripped into a cooling liquid having a temperature of maximally −5° C., thereby causing solidification of the solution or dispersion in the form of droplets, and wherein the solidified droplets or pellets are isolated and dried. The invention further relates to the use of these pellets in the manufacture of medicaments or diagnostic agents.
Abstract: The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
Type:
Grant
Filed:
August 9, 2000
Date of Patent:
August 3, 2004
Assignee:
Pharmacia AB
Inventors:
Bo Kreilgård, Lene Orup Jacobsen, Ulla Hoeck, Helle Kristensen, Torkel Gren, Lisbeth Nilvebrant, Anders Ringberg, Martin Wikberg, Bengt Hallén, Birgitta Olsson, Jan Strömbom
Abstract: A post hair removal skin lotion composition for use in reducing inflammation and irritation of skin immediately following hair removal by shaving, waxing, tweezing, electrolysis, or use of depilatory products, and for repairing skin damage resulting from these methods. The composition comprises deionized water, aloe vera gel, soybean oil, alpha lipoic acid, stearic acid, glyceryl monostearate, propylene glycol, lauramide DEA, vitamin E (tocopherol), hydrocortisone acetate, vitamin C (ascorbic acid), carbomer, hydroxymethylcellulose, methylparaben, propylparaben, and polyquaternium-15.
Abstract: A taste masked pharmaceutical composition comprising a microcapsule, wherein the microcapsule comprises a pharmaceutically active agent core coated with a taste masking effective amount of a water-insoluble enteric coating, wherein the coating comprises a weakly acidic methacrylic acid-ethyl acrylate copolymer.